# OnCo record nct05485766 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05485766/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05485766", "NCT05485766" ;
  schema:name "Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer"@en ;
  schema:description "A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel, carboplatin and olaparib in triple-negative breast cancer, run by Okayama University, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05485766/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05485766> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/olaparib/> .